Veeva RIM adopted by 450+ firms, including 19 top bio-pharmaceuticals.

Veeva Systems has announced that over 450 companies, including 19 of the 20 largest biopharmaceutical companies, have adopted Veeva RIM for regulatory information management on a unified platform. The company's continuous innovation to improve connectivity now includes partnerships with Accumulus Technologies and DNAnexus, allowing for integration with multiple regulatory authority platforms to boost efficiency and compliance. Veeva RIM's solution is accelerating time to market, improving global collaboration with stakeholders, and reducing compliance costs.

Veeva Systems (NYSE: VEEV) has announced that over 450 companies, including 19 of the 20 largest biopharmaceutical companies, have adopted Veeva RIM for regulatory information management on a unified platform. This adoption underscores the growing demand for streamlined regulatory processes and efficient data management in the life sciences sector.

Veeva RIM's capabilities are being further enhanced through strategic partnerships with Accumulus Technologies and DNAnexus. These collaborations enable integration with multiple regulatory authority platforms, facilitating greater connectivity and interoperability. The partnerships aim to modernize information sharing and accelerate regulatory submissions, thereby improving global stakeholder collaboration and reducing compliance costs.

Marc Gabriel, vice president of regulatory at Veeva, highlighted the benefits of the platform, stating, "Regulatory teams are adopting new Veeva product innovations to continually improve efficiency and reduce cycle times. Strengthened by industry partnerships, Veeva RIM provides an end-to-end solution that accelerates time to market, improves global stakeholder collaboration, and enables seamless data flow in a rapidly evolving regulatory environment."

Francisco Nogueira, CEO of Accumulus Technologies, emphasized the importance of these partnerships, "Our strategic partnership will connect the Accumulus platform and Veeva RIM for greater interoperability to modernize how information is instantly and simultaneously shared with our growing network of over 70 regulatory agencies worldwide. By facilitating seamless regulatory submissions, we can empower our mutual customers to get treatments to patients faster."

Thomas Laur, CEO of DNAnexus, added, "Integrating DNAnexus Trusted Regulatory Spaces (TRS) and Veeva RIM will provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals."

Veeva RIM is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. The platform's adoption is expected to drive significant efficiencies and cost savings for biopharmaceutical companies, particularly in the context of global regulatory compliance.

References:
[1] https://www.prnewswire.com/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542568.html
[2] https://www.ainvest.com/news/trump-demands-pharmaceutical-companies-justify-covid-drug-success-2509/